Literature DB >> 23423786

Expression and prognostic significance of GATA-binding protein 2 in colorectal cancer.

Lei Chen1, Beihai Jiang, Zaozao Wang, Maoxing Liu, Yiyuan Ma, Hong Yang, Jiadi Xing, Chenghai Zhang, Zhendan Yao, Nan Zhang, Ming Cui, Xiangqian Su.   

Abstract

GATA-binding protein 2 (GATA2) is a nuclear transcription factor that plays a critical role in tumorigenesis. High levels of GATA2 expression are correlated with poor survival outcomes in many types of cancer. However, the expression and prognostic significance of GATA2 in colorectal cancer remain unknown. In this study, GATA2 protein expression was examined using immunohistochemistry in 307 colorectal cancer tissues, and its association with clinicopathological features and prognosis was analyzed. The expression of GATA2 was found to be significantly higher in colorectal cancer tissues than in matched adjacent noncancerous tissues (60.3 vs. 9.0 %, P < 0.0001). The expression of GATA2 was significantly correlated with tumor location (P = 0.005), histological type (P = 0.019), and recurrence (P = 0.009). Kaplan-Meier survival analysis demonstrated that patients with high levels of GATA2 expression had worse disease-free survival outcomes than those with low levels of GATA2 expression (P = 0.016). Univariate analysis showed high levels of GATA2 expression to be significantly associated with shorter periods of disease-free survival (HR 2.196; 95 % CI 1.142-4.226; P = 0.018). Multivariate analysis showed GATA2 expression to be an independent prognostic factor for patients with colorectal cancer (HR 1.952; 95 % CI 1.010-3.775; P = 0.047). These findings suggest that high levels of GATA2 expression may be a useful indicator of disease recurrence after curative colorectal cancer treatment.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23423786     DOI: 10.1007/s12032-013-0498-7

Source DB:  PubMed          Journal:  Med Oncol        ISSN: 1357-0560            Impact factor:   3.064


  27 in total

1.  The human beta-globin gene 3' enhancer contains multiple binding sites for an erythroid-specific protein.

Authors:  L Wall; E deBoer; F Grosveld
Journal:  Genes Dev       Date:  1988-09       Impact factor: 11.361

2.  Screening for colorectal cancer: a guidance statement from the American College of Physicians.

Authors:  Amir Qaseem; Thomas D Denberg; Robert H Hopkins; Linda L Humphrey; Joel Levine; Donna E Sweet; Paul Shekelle
Journal:  Ann Intern Med       Date:  2012-03-06       Impact factor: 25.391

3.  Survival in patients with large-bowel cancer. A population-based investigation from the Melbourne Colorectal Cancer Study.

Authors:  G A Kune; S Kune; B Field; R White; W Brough; R Schellenberger; L F Watson
Journal:  Dis Colon Rectum       Date:  1990-11       Impact factor: 4.585

4.  The GATA2 transcriptional network is requisite for RAS oncogene-driven non-small cell lung cancer.

Authors:  Madhu S Kumar; David C Hancock; Miriam Molina-Arcas; Michael Steckel; Phillip East; Markus Diefenbacher; Elena Armenteros-Monterroso; François Lassailly; Nik Matthews; Emma Nye; Gordon Stamp; Axel Behrens; Julian Downward
Journal:  Cell       Date:  2012-04-27       Impact factor: 41.582

Review 5.  Colorectal cancer.

Authors:  David Cunningham; Wendy Atkin; Heinz-Josef Lenz; Henry T Lynch; Bruce Minsky; Bernard Nordlinger; Naureen Starling
Journal:  Lancet       Date:  2010-03-20       Impact factor: 79.321

6.  An early haematopoietic defect in mice lacking the transcription factor GATA-2.

Authors:  F Y Tsai; G Keller; F C Kuo; M Weiss; J Chen; M Rosenblatt; F W Alt; S H Orkin
Journal:  Nature       Date:  1994-09-15       Impact factor: 49.962

7.  Gain-of-function mutation of GATA-2 in acute myeloid transformation of chronic myeloid leukemia.

Authors:  Su-Jiang Zhang; Li-Yuan Ma; Qiu-Hua Huang; Guo Li; Bai-Wei Gu; Xiao-Dong Gao; Jing-Yi Shi; Yue-Ying Wang; Li Gao; Xun Cai; Rui-Bao Ren; Jiang Zhu; Zhu Chen; Sai-Juan Chen
Journal:  Proc Natl Acad Sci U S A       Date:  2008-02-04       Impact factor: 11.205

8.  Determination of synthetic lethal interactions in KRAS oncogene-dependent cancer cells reveals novel therapeutic targeting strategies.

Authors:  Michael Steckel; Miriam Molina-Arcas; Britta Weigelt; Michaela Marani; Patricia H Warne; Hanna Kuznetsov; Gavin Kelly; Becky Saunders; Michael Howell; Julian Downward; David C Hancock
Journal:  Cell Res       Date:  2012-05-22       Impact factor: 25.617

9.  Overall survival after resection for colon cancer in a national cohort study was adversely affected by TNM stage, lymph node ratio, gender, and old age.

Authors:  Kristian E Storli; Karl Søndenaa; Ida R K Bukholm; Idunn Nesvik; Tore Bru; Bjørg Furnes; Bjarte Hjelmeland; Knut B Iversen; Geir E Eide
Journal:  Int J Colorectal Dis       Date:  2011-05-12       Impact factor: 2.571

10.  Prediction of metastasis and recurrence in colorectal cancer based on gene expression analysis: ready for the clinic?

Authors:  Masaki Shibayama; Matthias Maak; Ulrich Nitsche; Kengo Gotoh; Robert Rosenberg; Klaus-Peter Janssen
Journal:  Cancers (Basel)       Date:  2011-07-07       Impact factor: 6.639

View more
  7 in total

1.  Decreased mRNA expression of GATA1 and GATA2 is associated with tumor aggressiveness and poor outcome in clear cell renal cell carcinoma.

Authors:  Inga Peters; Natalia Dubrowinskaja; Hossein Tezval; Mario W Kramer; Christoph A von Klot; Jörg Hennenlotter; Arnulf Stenzl; Ralph Scherer; Markus A Kuczyk; Jürgen Serth
Journal:  Target Oncol       Date:  2014-09-19       Impact factor: 4.493

2.  Combined preoperative CEA and CD44v6 improves prognostic value in patients with stage I and stage II colorectal cancer.

Authors:  L Chen; B Jiang; Z Wang; M Liu; H Yang; J Xing; C Zhang; Z Yao; N Zhang; M Cui; X Su
Journal:  Clin Transl Oncol       Date:  2013-07-17       Impact factor: 3.405

3.  ENCAPP: elastic-net-based prognosis prediction and biomarker discovery for human cancers.

Authors:  Jishnu Das; Kaitlyn M Gayvert; Florentina Bunea; Marten H Wegkamp; Haiyuan Yu
Journal:  BMC Genomics       Date:  2015-04-03       Impact factor: 3.969

4.  GOLPH3 predicts survival of colorectal cancer patients treated with 5-fluorouracil-based adjuvant chemotherapy.

Authors:  Zaozao Wang; Beihai Jiang; Lei Chen; Jiabo Di; Ming Cui; Maoxing Liu; Yiyuan Ma; Hong Yang; Jiadi Xing; Chenghai Zhang; Zhendan Yao; Nan Zhang; Bin Dong; Jiafu Ji; Xiangqian Su
Journal:  J Transl Med       Date:  2014-01-21       Impact factor: 5.531

5.  SMAR1 favors immunosurveillance of cancer cells by modulating calnexin and MHC I expression.

Authors:  Aftab Alam; Nandaraj Taye; Sonal Patel; Milind Thube; Jayati Mullick; Vibhuti Kumar Shah; Richa Pant; Tanaya Roychowdhury; Nilanjan Banerjee; Subhrangsu Chatterjee; Rittwika Bhattacharya; Rini Roy; Ashis Mukhopadhyay; Devraj Mogare; Samit Chattopadhyay
Journal:  Neoplasia       Date:  2019-08-15       Impact factor: 5.715

6.  A feedback loop between GATA2-AS1 and GATA2 promotes colorectal cancer cell proliferation, invasion, epithelial-mesenchymal transition and stemness via recruiting DDX3X.

Authors:  Yuliang Pan; Yuxing Zhu; Jun Zhang; Long Jin; Peiguo Cao
Journal:  J Transl Med       Date:  2022-06-25       Impact factor: 8.440

7.  GATA2 rs2335052 Polymorphism Predicts the Survival of Patients with Colorectal Cancer.

Authors:  Xijuan Liu; Beihai Jiang; Aidong Wang; Jiabo Di; Zaozao Wang; Lei Chen; Xiangqian Su
Journal:  PLoS One       Date:  2015-08-19       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.